Ignite Creation Date:
2024-05-06 @ 1:08 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03940625
Status:
COMPLETED
Last Update Posted:
2022-05-25
First Post:
2019-05-06
Brief Title:
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping
Sponsor:
Heinrich-Heine University Duesseldorf
Organization:
Heinrich-Heine University Duesseldorf
Study Overview
Official Title:
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANKE
Brief Summary:
Anthracyclines eg Doxorubicin are an important and highly effective chemotherapeutic They are used in various tumor entities and are established for breast cancer treatment The most significant prognostic side effect is cardiotoxicity which occurs in up to 50 patients Female gender must be considered an independent risk factor for the incidence and severity of associated heart failure The aim of this study is to demonstrate that dose-dependent anthracycline-induced cardiotoxicity has a measurable effect on T2 mapping on MRI The second aim is to demonstrate if the combination of diastolic strain echo and MRI and T2 mapping can detect earlier anthracycline-induced myocardial damage than via the established method of the echocardiographic measurement of LV-EF and the conventional quantification of diastolic function
Detailed Description:
In order to answer the question patients with breast cancer who will undergo a chemotherapeutic treatment with antracycline will be examined before chemotherapy including cmr and echocardiography and after chemotherapy at different times within one year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None